Medication info
DIAFAB SMET Tablet 50/850 mg (Vildagliptin, Metformin Hydrochloride)

DIAFAB SMET Tablet 50/850 mg (Vildagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Hankook Hyutecs Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202302280 · Approved 2023.07.28 · Insurance code 649105780

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. Doses of vildagliptin of 100mg or more per day are not recommended. This medicine should generally be taken with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients with no prior experience of antidiabetic drug therapy in whom adequate glycemic control is not achieved with monotherapy: The initial dose of this medicine is 1 tablet of 50/500mg once daily. The dose may be gradually increased to 1 tablet of 50/1000mg 2 times daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide vildagliptin 100mg per day and the patient's existing dose of metformin. The initial dose of this medicine should be determined according to the patient's current treatment regimen; take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg in the morning and evening, 2 times daily. 3. Patients switching from concomitant therapy with vildagliptin and metformin: Patients switching from concomitant therapy with vildagliptin and metformin to this medicine may start at their existing doses of vildagliptin and metformin. 4. When used in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg 2 times daily (total daily dose 100mg) and administer metformin at a dose similar to the existing dose. - When this medicine is used in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to lower the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching from other oral antidiabetic agents to this medicine. Any change in type 2 diabetes treatment may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is time to take the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal before starting this medicine.

Ingredients

Manufacturer
Hankook Hyutecs Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is prescribed to help control blood sugar levels in patients with type 2 diabetes using vildagliptin and metformin together. It assists in effectively managing blood sugar through dietary and exercise regimes. This helps stabilize blood sugar levels and contributes to the prevention of diabetes-related complications. It plays an important role in maintaining healthy blood sugar levels for patients.

How to take

Adult dose

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. Doses of vildagliptin of 100mg or more per day are not recommended. This medicine should generally be taken with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients with no prior experience of antidiabetic drug therapy in whom adequate glycemic control is not achieved with monotherapy: The initial dose of this medicine is 1 tablet of 50/500mg once daily. The dose may be gradually increased to 1 tablet of 50/1000mg 2 times daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide vildagliptin 100mg per day and the patient's existing dose of metformin. The initial dose of this medicine should be determined according to the patient's current treatment regimen; take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg in the morning and evening, 2 times daily. 3. Patients switching from concomitant therapy with vildagliptin and metformin: Patients switching from concomitant therapy with vildagliptin and metformin to this medicine may start at their existing doses of vildagliptin and metformin. 4. When used in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg 2 times daily (total daily dose 100mg) and administer metformin at a dose similar to the existing dose. - When this medicine is used in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to lower the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching from other oral antidiabetic agents to this medicine. Any change in type 2 diabetes treatment may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is time to take the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal before starting this medicine.

Precautions

This medication may cause severe lactic acidosis or hypoglycemia, thus caution is required. It should not be administered to patients with moderate to severe kidney impairment, heart failure, acute cardiac diseases, or sepsis. If the patient is scheduled for a test using iodine contrast agents, this medication should be discontinued 48 hours prior to the test, and it should only be resumed once kidney function is confirmed normal. Patients with hypersensitivity to this medication or with type 1 diabetes or diabetic ketoacidosis should not use it. In cases of severe infections, serious trauma with systemic involvement, pre- and post-surgery, malnutrition, or liver or lung function impairment, its use should be temporarily halted or approached with caution. Pregnant or nursing women are advised against using this medication. While this medication lowers blood sugar, irregular meals, intense exercise, or concurrent use with other medications may increase the risk of hypoglycemia. Regular monitoring of liver and kidney functions is necessary during treatment. If symptoms of acute pancreatitis arise, discontinue use immediately and consult a doctor. Alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid it. If symptoms of hypoglycemia occur, sugar should be consumed immediately, and consultation with a doctor is recommended if necessary. Older adults may have decreased kidney function, so dose adjustment and regular function tests are necessary. If surgery is scheduled, discontinue this medication 48 hours prior to the operation and resume it after observing the progress post-surgery. This medication is not recommended for children and adolescents. In cases of overdose, seek medical attention immediately, and this medication can be partially removed by hemodialysis. It should be stored out of reach of children and not transferred to other containers. Any abnormal symptoms like blisters or ulcers on the skin during treatment should be reported to a doctor immediately. Patients with symptoms similar to diabetes unrelated to diabetes should have the treatment decision made after an accurate diagnosis. Regular blood sugar and glycated hemoglobin measurements should be conducted to monitor treatment effectiveness. Vitamin B12 levels may decrease, so regular blood tests are necessary, and appropriate action should be taken if abnormalities are found. Symptoms like joint pain or skin rashes may manifest during treatment, so careful observation is necessary.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • hepatitis
  • liver dysfunction
  • elevated transaminase levels
  • angioedema
  • tremors
  • headache
  • dizziness
  • fatigue
Show 45 more
  • nausea
  • hypoglycemia
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • decreased blood glucose
  • asthenia
  • sweating
  • constipation
  • arthralgia
  • upper respiratory tract infection
  • nasopharyngitis
  • peripheral edema
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • decreased appetite
  • taste disturbance
  • erythema
  • pruritus
  • urticaria
  • pancreatitis
  • urticaria
  • blisters
  • exfoliative skin lesions
  • severe arthralgia
  • cutaneous vasculitis
  • cholecystitis
  • dyspepsia
  • abdominal discomfort
  • gastrointestinal abnormalities
  • increased serum amylase
  • increased lipase
  • vesicular pemphigoid
  • myalgia
  • paresthesia
  • fever
  • edema
  • swelling of hands and feet
  • elevated creatine phosphokinase
  • elevated AST
  • increased C-reactive protein
  • elevated myoglobin levels

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly closed container in a dry place. Additionally, it is best stored in a cool place below 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.